New stent for opening sinuses

Thirty one million Americans suffer from chronic sinusitis.

When medications fail, seeking relief can often lead to surgery.

Now there's a new device that can help guarantee permanent results.
The tables are turned as nurse Jillian Giertuga undergoes a cat scan.

"I had constant pressure in my cheeks and forehead," Jillian says.

She was suffering from chronic sinusitis.

Jordan Pritikin is the physician-director of the Chicago Nasal & Sinus Center.

"Chronic sinusitis is an inflammation of the tissues that line the air filled cavities within the skull," he says.

When steroids, decongestants, and antibiotics fail surgery becomes an option.

"We are opening up this space to allow air to flow, allow mucus to drain, and to get rid of as much diseased tissue as possible."

Up to 20 percent of nasal surgeries fail due to scarring or recurrent inflammation. Now, Pritikin is using a stent that holds the sinuses open.

"Doesn't interfere with the drainage, doesn't interfere with airflow, but more importantly it's coated with a steroid that slowly releases into the tissues to decrease inflammation."

The stent is absorbed by the body-patients find long term relief.

"Things are much better, no pressure, no headaches," Jillian says.

And hopefully just the beginning of breathing easier.

Half a million patients each year undergo surgery to treat sinusitis.

Studies show the propel implants have provided a 29-percent reduction in the need for postoperative interventions.


REPORT: MB # 3723

BACKGROUND: Sinusitis is an inflammation, or swelling, of tissue lining the sinuses. This happens when the sinuses become clogged and are filled with fluid. Sinuses should be filled with air, but when they are blocked and filled with fluid, germs can grow and cause an infection. There are different types of sinusitis: chronic sinusitis, acute sinusitis, recurrent sinusitis, and subacute sinusitis. Almost 37 million people in the U.S. suffer from at least one episode of sinusitis a year. (Source:
CAUSES: Sinusitis may be caused by a number of things, but those who have a common cold, swelling of the nose, nasal polyps, or a deviated septum have a larger risk of developing the infection. Fungal infections, especially in people with impaired immune systems, can develop the infection and it may be more difficult to treat because sinusitis is viral, not bacterial. (Source:
PROPEL STEROID-RELEASING IMPLANT: The newest treatment for sinusitis is the PROPEL dissolvable implant for chronic sinusitis patients undergoing sinus surgery. PROPEL is the first of a new category of products offering localized, controlled drug delivery directly to the sinus tissue. It is inserted by a physician to maintain the surgical opening, the spring-like implant expands to prop open the ethmoid sinus and gradually delivers an advanced corticosteroid with anti-inflammatory properties directly to the sinus lining as the implant dissolves. Safety and efficacy of the PROPEL implant has been studied in three prospective clinical trials in the U.S., with a total of 205 patients enrolled.
* A randomized, controlled, double-blind Pilot study, recognized with the 2010 Maurice Cottle Research Award honoring best clinical or basic science by the American Rhinologic Society (ARS).
* The ADVANCE single-cohort study that assessed safety, endoscopic outcomes and patient symptoms to 6 months.
* The ADVANCE II randomized, controlled, double-blind clinical trial, which included review by an independent panel of surgeons. (Source:


Jordan Pritikin, MD
Chicago Nasal & Sinus Center

If this story or any other Ivanhoe story has impacted your life or prompted you or someone you know to seek or change treatments, please let us know by contacting Marjorie Bekaert Thomas at

Comments are posted from viewers like you and do not always reflect the views of this station.
powered by Disqus
WNDU - Channel 16 54516 State Road 933 South Bend, IN 46637 Front Desk: 574-284-3000 Newsroom: 574-284-3016 Email:
Gray Television, Inc. - Copyright © 2002-2014 - Designed by Gray Digital Media - Powered by Clickability 241514621 -